STOCK TITAN

IGC Pharma Inc - IGC STOCK NEWS

Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.

IGC Pharma Inc (NYSE American: IGC) is a clinical-stage biotechnology leader pioneering AI-driven cannabinoid therapies for Alzheimer’s disease, chronic pain, and neurological disorders. This page provides investors and researchers with timely updates on the company’s pharmaceutical advancements, clinical trial progress, and strategic initiatives.

Access comprehensive coverage of IGC’s investigational drug pipeline, including IGC-AD1 for Alzheimer’s-related agitation currently in Phase 2 trials. Stay informed about cutting-edge research integrating artificial intelligence to optimize therapeutic development and diagnostic precision.

Explore updates across key areas: clinical trial milestones, regulatory developments, research partnerships, and product launches from the Holiby™ wellness brand. Our curated news collection ensures you never miss critical updates about IGC’s dual focus on pharmaceutical innovation and consumer health solutions.

Bookmark this page for verified information on IGC Pharma’s advancements in cannabinoid science, AI applications in drug discovery, and market-moving developments. Check regularly for authoritative reporting on one of biotech’s most innovative players.

Rhea-AI Summary

IGC Pharma reported Q2 FY2025 results with significant pipeline developments in Alzheimer's treatments. Revenue grew 42% to $412,000, while net loss decreased to $1.7 million ($0.02 per share) from $2.5 million ($0.05 per share) in Q2 FY2024. The quarter highlighted progress in multiple compounds: TGR-63 demonstrated blood-brain barrier crossing ability, IGC-1A was identified as a potential GLP-1 agonist through AI modeling, IGC-1C showed promising preclinical results targeting tau protein, and IGC-AD1 advanced as a dual-action disease-modifying therapy. SG&A expenses decreased 25% to $1 million, and R&D expenses reduced 28% to $917,000.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
-
Rhea-AI Summary

IGC Pharma announces the publication of an interview with CEO Ram Mukunda in the IMS Spotlight Series. The interview highlights the company's strategic expansion into metabolic and neurological markets, focusing on GLP-1 agonists for both Alzheimer's and weight loss therapies. Mukunda discusses updates on IGC-AD1, their lead candidate currently in Phase 2 trials for treating agitation in Alzheimer's dementia, which is advancing toward additional trials for potential disease-modifying treatment. The company emphasizes its use of artificial intelligence to diversify its pipeline across neurodegenerative and metabolic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary

IGC Pharma (NYSE American:IGC) has announced the enrollment of patients at Baycrest Academy for Research and Education in Toronto, Canada, for its ongoing Phase 2 trial of IGC-AD1, a treatment for agitation in Alzheimer's dementia. IGC-AD1 is a partial CB1 receptor agonist with anti-neuroinflammatory properties, targeting key pathways involved in Alzheimer's disease pathology. The trial expansion to Canada follows approval from Health Canada.

Dr. Howard Chertkow, Chair of Cognitive Neurology and Innovation at Baycrest, emphasized the importance of this study in addressing behavioral symptoms of Alzheimer's. The trial will enroll 164 patients, with half receiving IGC-AD1 and half receiving a placebo. IGC Pharma currently has 12 U.S. trial sites under contract and plans to add more in Canada to increase population diversity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
Rhea-AI Summary

IGC Pharma, Inc. (NYSE American:IGC) has won two awards in Phase 1 of the National Institute on Aging's PREPARE Challenge, which aims to accelerate the development of tools for Alzheimer's and related dementias. The company's entry, using the Mexican Health and Aging Study database, won the Disproportionate Impact prize and placed third overall.

IGC is developing AI and deep learning models to predict cognitive decline up to 20 years before symptoms appear, potentially improving patient outcomes and reducing healthcare costs. CEO Ram Mukunda stated that these recognitions underscore IGC's leadership in AI research for Alzheimer's disease prediction and could help address the projected $1 trillion economic burden on the U.S. healthcare system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
-
Rhea-AI Summary

IGC Pharma (NYSE American: IGC) has announced promising preclinical data for IGC-AD1, its potential Alzheimer's disease treatment. The drug demonstrates the ability to modify tau pathology and improve spatial memory, building on previous findings of amyloid plaque reduction. Key results include:

1. 10% reduction in the ratio of phosphorylated tau to total tau
2. 35% reduction in GSK3 enzyme expression
3. 50% faster improvement in spatial memory tests

IGC-AD1 is currently in a Phase 2 clinical trial for agitation in Alzheimer's, with over 1,000 oral doses administered and no dose-limiting adverse events observed. The company aims to position IGC-AD1 for two large indications: agitation in Alzheimer's and as a disease-modifying anti-amyloid/anti-tangle treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
-
Rhea-AI Summary

IGC Pharma (NYSE American: IGC) is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer's disease. Following FDA approvals of anti-amyloid drugs in 2023, IGC-AD1 shows promise with its oral administration and strong safety profile. Preliminary data suggests IGC-AD1 may reduce plaque aggregation by ~20% and decrease production by up to 40% without affecting essential Amyloid Precursor Protein (APP) production. The company plans to initiate disease-modifying investigational trials in early 2025, positioning itself in a significant market opportunity. IGC-AD1 is currently in Phase 2 clinical trials for treating agitation in Alzheimer's dementia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
Rhea-AI Summary

IGC Pharma (NYSE American: IGC) held its Annual Meeting of Stockholders on August 23, 2023, where all proposals disclosed in the Definitive Proxy Statement were approved. Key decisions include:

  • Election of Richard Prins and Terry Lierman as Class B directors until the 2027 annual meeting
  • Ratification of Manohar Chowdhry & Associates as the independent registered public accounting firm for fiscal year 2025
  • Approval to grant 5,000,000 shares of common stock to current and new employees, advisors, directors, and consultants, subject to performance metrics set by the board or CEO

Only stockholders of record as of June 28, 2024, were eligible to vote at the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
Rhea-AI Summary

IGC Pharma (NYSE American: IGC) has announced promising preclinical research on IGC-1C, a novel small-molecule modulator. The findings reveal that IGC-1C targets tau protein phase separation, offering new possibilities for treating neurodegenerative diseases. Additionally, IGC-1C has been identified as a potential GLP-1 receptor agonist, showing promise for weight loss treatments and presenting a unique strategy to combat Alzheimer's disease.

Key points:

  • IGC-1C exhibits a dissociation constant (Kd) of 3.95 ± 0.32 μM with tau, indicating strong binding affinity
  • The molecule effectively inhibits tau condensates and prevents their transition into toxic fibrils
  • IGC-1C's dual action targets both tau and GLP-1 receptors, potentially addressing multiple pathways in Alzheimer's and metabolic disorders
  • The company aims to advance IGC-1C through future clinical trials
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
none
-
Rhea-AI Summary

IGC Pharma (NYSE American: IGC) has announced that its proprietary molecule, IGC-1A, has been identified as a potential GLP-1 agonist through AI modeling. This discovery marks a significant milestone for the company, potentially expanding its portfolio to include metabolic disorders and weight loss treatments. GLP-1 agonists are known for managing blood sugar levels and promoting weight loss, with potential neuroprotective benefits for Alzheimer's disease.

CEO Ram Mukunda highlighted that IGC-1A and IGC-1C could become effective options for metabolic disorders, comparing favorably to established drugs like Ozempic and Metformin. The company plans to progress with toxicology and dosing studies in 2024, aiming to submit an Investigational New Drug Application to the FDA for IGC-1A.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags
none
Rhea-AI Summary

IGC Pharma reported its Q1 FY2025 results, highlighting significant progress in its Alzheimer's research portfolio. The company's lead drug candidate, IGC-AD1, showed promising interim data in its Phase 2 clinical trial for agitation in Alzheimer's. Additionally, TGR-63 demonstrated positive pre-clinical results in an Alzheimer's mouse model. Despite these advancements, IGC's revenue decreased by 51% to $272,000 compared to the same period last year. The company's R&D expenses increased by 19% to $889,000, reflecting the expansion of clinical trials. The net loss for the quarter was $2.4 million or $0.03 per share. IGC also extended its $12 million loan agreement with O-Bank for another year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
IGC Pharma Inc

NYSE:IGC

IGC Rankings

IGC Stock Data

20.97M
73.70M
7.52%
20.91%
1.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
POTOMAC